Morinda citrifolia (Noni) exhibits potential therapeutic activities for treating central nervous system disorders by targeting mainly receptors, enzyme transporters, and has neuroprotective activity.
The research involved gathering existing scholarly literature across databases such as ResearchGate, Medline, and Wikipedia. It focused on the impact of the Noni plant on receptors, enzyme transporters, and the various methods for evaluating CNS disorders. The antidepressant effects of the Morinda citrifolia fruit were assessed in vitro using Monoamine Oxidase (MAO) A and B bioassays. The antipsychotic activity was determined by measuring the degree of inhibition of dopaminergic receptors by the Methanolic extract of Noni.
In the discussion of the results, the findings suggested that Morinda citrifolia fruit has potential therapeutic benefits. The Noni fruit appears to work synergistically due to its constituent active compounds that inhibit MAOA and MAOB enzymes, displaying antidepressant activity. Moreover, it showed an antipsychotic activity attributed to the Methanolic extract of Noni inhibiting dopaminergic receptors. Other notable activities include anti-craving for alcohol dependence, judged by CPP test, anxiolytic activity exhibited by the administration of benzodiazepine and MMC in mouse models, and also neuroprotective ability by reducing brain impairment caused by reperfusion injury.
